ESR2 and female reproductive system neoplasm: Although primarily visualizing ERα, [18F]-FES-PET has also shown efficacy in assessing ER status in gynecological tumors predominantly expressing ERβ, with ongoing efforts to develop specific ERβ tracers [33,34].